Providence Cancer Institute shares updates on advances in care for melanoma patients

Providence Cancer Institute shares updates on advances in care for melanoma patients

In early October, Providence Cancer Institute of Oregon and AIM at Melanoma Foundation held a virtual patient education event for people with melanoma, plus their family and friends.

Watch full presentations here

Talks included: 

  • "Basics of Clinical Trials,” presented by Chris Fountain, RN, Clinician-Research, Providence Cancer Institute (video)

  • “Case Studies Illustrating Recent Advances in Medical Care,” presented by Brendan D. Curti, M.D., Medical Oncologist, Medical Director, Providence Melanoma Program, Providence Cancer Institute (video)

  • “New Treatments Under Development in Melanoma,” presented by Matthew H. Taylor, M.D., Medical Oncologist, Co-Medical Director, Providence Melanoma Program, Providence Cancer Institute (video)

  • “Communication with Family & Friends,” presented by Dawn Brucker, LCSW, OSW-C, Oncology Social Worker, Providence Cancer Institute (video)

We host a variety of classes, educational talks, and other events throughout the year. Learn more at providence.org.

Related news

Multi-indication clinical trials help evaluate new medications for future treatments

Studies will evaluate combination therapies for two types of melanoma

Melanoma studies: can adjuvant immunotherapy improve recurrence-free survival?

1/30/2023
Using MRI-guided radiation, Providence radiation oncologists can precisely target tumors for destruction while minimizing damage to surrounding normal tissue.
1/13/2023
A new clinical trial offered at Providence Cancer Institute to study the safety and effectiveness of two different treatments for people under age 70 with previously untreated non-GCB DLBCL.
12/20/2022
Providence Cancer Institute highlights a year of engaging with and supporting our patients, partner organizations and community.
12/6/2022
Providence Cancer Institute is offering a phase III trial for patients with gynecologic cancers and two early phase trials that will study new medications in treating solid tumors.